Patient-Friendly Explanation

MariTide is an investigational weight loss medication developed by Amgen. It works differently from current treatments by targeting two hormone pathways at once — activating GLP-1 (which reduces appetite) while blocking GIP (which may enhance fat burning).

Clinical Definition

Maridebart cafraglutide (MariTide) is a bispecific molecule combining a GLP-1 receptor agonist with a GIP receptor antagonist conjugated to an anti-GIP antibody. In Phase 2 clinical trials, MariTide demonstrated up to 20% body weight reduction at 52 weeks with monthly or less frequent dosing, offering a favourable dosing schedule compared to weekly injectables.

Why It Matters

MariTide represents a new class of weight loss pharmacotherapy that may offer sustained results with fewer injections. NuLifeCare Singapore stays current with emerging obesity treatments and can help patients understand their options as new medications become available in Singapore.